Suppr超能文献

管腔型乳腺癌患者的五年生存率:与肿瘤内蛋白酶体活性的关系

Five-year survival in luminal breast cancer patients: relation with intratumoral activity of proteasomes.

作者信息

Sereda Elena E, Kolegova Elena S, Kakurina Gelena V, Korshunov Dmitriy A, Sidenko Evgenia A, Doroshenko Artem V, Slonimskaya Elena M, Kondakova Irina V

机构信息

Laboratory of Tumor Biochemistry, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia.

Department of Biochemistry and Molecular Biology, Faculty of Medicine and Biology, Siberian State Medical University, Tomsk, Russia.

出版信息

Transl Breast Cancer Res. 2022 Jul 30;3:23. doi: 10.21037/tbcr-22-22. eCollection 2022.

Abstract

BACKGROUND

The purpose of the study was to analyze the relationship between the caspase-like (CL) and chymotrypsin-like (ChTL) activities of proteasomes and the 5-year overall and metastasis-free survival rates in patients with luminal breast cancer.

METHODS

The study included 117 patients with primary operable invasive breast cancer (TNM). Tissue samples from breast cancer patients were obtained as a result of the radical mastectomy or breast conserving surgery, which was a first line of therapy. The ChTL and CL proteasomes activities in the tumor tissue and in the surrounding adjacent breast tissues were assessed using the fluorometric method. The coefficients of ChTL (cChTL) and CL (cCL) proteasomes activities were also determined. The coefficients were calculated as the ratio of the corresponding proteasomes activity in the tumor tissue to the surrounding adjacent breast tissues. Within 5 years of follow-up, hematogenous metastases occurred in 14% of patients with luminal A breast cancer, in 31% of patients with luminal B human epidermal growth factor receptor-2 (HER-2) negative and in 23% of patients with luminal B HER-2 positive breast cancers. The study protocol was approved by the Local Ethics Committee of the Cancer Research Institute of Tomsk National Research Medical Center. Written informed consent was obtained from all patients.

RESULTS

An increase in the ChTL and CL proteasomes activities was shown in all studied molecular subtypes of breast cancer compared to adjacent tissues. It was found that the cChTL of >35.9 U/mg protein and the cCL of >2.21 in breast cancer patients were associated with the development of distant metastases. In patients with luminal A breast cancer, the 5-year metastasis-free survival rates were associated only with the value of cCL of proteasomes (log-rank test: P=0.008). In patients with luminal B HER-2 negative breast cancer, the 5-year metastasis-free survival rates were associated with the levels of ChTL and cCL proteasomes activities (log-rank test: P=0.02 and P=0.04, respectively).

CONCLUSIONS

The data obtained on the correlation of 5-year metastasis-free survival rates with the level of proteasomes activities indicate the possibility of their use as additional prognostic criteria for breast cancer.

摘要

背景

本研究旨在分析蛋白酶体的半胱天冬酶样(CL)和胰凝乳蛋白酶样(ChTL)活性与腔面型乳腺癌患者5年总生存率和无转移生存率之间的关系。

方法

本研究纳入了117例原发性可手术浸润性乳腺癌(TNM)患者。乳腺癌患者的组织样本取自根治性乳房切除术或保乳手术,这是一线治疗方法。采用荧光法评估肿瘤组织及周围相邻乳腺组织中的ChTL和CL蛋白酶体活性。还测定了ChTL(cChTL)和CL(cCL)蛋白酶体活性系数。系数计算为肿瘤组织中相应蛋白酶体活性与周围相邻乳腺组织中相应蛋白酶体活性的比值。在5年的随访中,14%的腔面A型乳腺癌患者、31%的腔面B型人表皮生长因子受体2(HER-2)阴性患者和23%的腔面B型HER-2阳性乳腺癌患者发生血行转移。本研究方案已获得托木斯克国立研究医学中心癌症研究所当地伦理委员会的批准。所有患者均获得书面知情同意。

结果

与相邻组织相比,所有研究的乳腺癌分子亚型中ChTL和CL蛋白酶体活性均升高。发现乳腺癌患者中cChTL>35.9 U/mg蛋白和cCL>2.21与远处转移的发生有关。在腔面A型乳腺癌患者中,5年无转移生存率仅与蛋白酶体的cCL值相关(对数秩检验:P=0.008)。在腔面B型HER-2阴性乳腺癌患者中,5年无转移生存率与ChTL和cCL蛋白酶体活性水平相关(对数秩检验:分别为P=0.02和P=0.04)。

结论

关于5年无转移生存率与蛋白酶体活性水平相关性的数据表明,它们有可能作为乳腺癌的额外预后标准。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4aee/11093047/cfe382ac5c96/tbcr-03-23-f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验